# Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

> **NCT06820281** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Garvan Institute of Medical Research** · enrollment: 44 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Tirzepatide 2.5mg weekly
- **DRUG:** Placebo injection (normal saline)

## Key facts

- **NCT ID:** NCT06820281
- **Lead sponsor:** Garvan Institute of Medical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06820281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06820281, "Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06820281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*